Table 1

Baseline characteristics

Baseline characteristicsUsual care
(n=122)
CRT-CPW
(n=115)
P value*
Male90 (73.8%)81 (70.4%)0.66
Age (years)0.16
 18–6435 (28.7%)24 (20.9%)
 65–7443 (35.2%)45 (39.1%)
 75–9944 (36.1%)46 (40.0%)
NYHA class0.071
 Class I5 (4.1%)6 (5.2%)
 Class II70 (57.4%)46 (40.0%)
 Class III25 (20.5%)29 (25.2%)
 Class IV1 (0.8%)5 (4.3%)
 Missing21 (17.2%)29 (25.2%)
 LBBB61 (50.0%)59 (51.3%)0.90
 QRS duration (ms)161.5±29.1159.7±29.20.62
 LVEF (%)29.4±8.430.2±8.80.50
 Ischaemic cardiomyopathy52 (42.6%)59 (51.3%)0.19
 Hypertension48 (39.3%)41 (35.7%)0.59
 Myocardial infarction41 (33.6%)55 (47.8%)0.034
 Atrial fibrillation49 (40.2%)57 (49.6%)0.15
 Chronic lung disease18 (14.8%)14 (12.2%)0.58
 Diabetes21 (17.2%)32 (27.8%)0.061
 Glomerular filtration rate (MDRD formula)62.2±27.559.4±21.10.38
 Beta blocker103 (84.4%)98 (85.2%)1.00
 ACEi / ARB106 (86.9%)99 (86.1%)1.00
 MRA56 (45.9%)68 (59.1%)0.051
 Upgrade15 (12.3%)27 (23.5%)0.027
 ICD90 (73.8%)79 (68.7%)0.39
  • *P-value comparesusual care and the CRT- CPW. Tests used are Student t-test,Cochran-Mantel-Haenszel test, Fisher exact test. P-value<0.05 is considered significant

  • ACEi, angiotensin-converting enzyme-inhibitor; ARB, angiotensin II-receptor blocker; CRT, cardiac resynchronisation therapy; CRT-CPW, CRT care pathway; ICD, implantable cardioverter-defibrillator; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart Association.